Treatment Pathway
Treatment of Infective Endocarditis
Infective endocarditis is infection of the inner heart lining, particularly the heart valves. It is a serious condition requiring prolonged intravenous antibiotics and sometimes surgery.
ESC (European Society of Cardiology)ACC/AHA (American Heart Association)NICE (UK)WHO Cardiovascular Guidelines
Infective endocarditis is infection of the inner heart lining, particularly the heart valves. It is a serious condition requiring prolonged intravenous antibiotics and sometimes surgery.
First-Line Treatment Principles
- ✓Risk factor modification: target BP <130/80 mmHg in most patients, LDL according to risk category
- ✓Antiplatelet therapy (aspirin or P2Y12 inhibitor) for established atherosclerotic disease
- ✓ACE inhibitor or ARB for heart failure with reduced ejection fraction (HFrEF) and post-MI LV dysfunction
- ✓Beta-blocker for rate control, post-MI, and stable HFrEF
- ✓Statin therapy for all patients with established ASCVD or high CV risk
Non-Pharmacological Management
- •Cardiac rehabilitation program after MI, HF, or revascularisation
- •Dietary modification: Mediterranean or DASH diet; restrict sodium <2g/day in HF
- •Regular aerobic exercise: 150 min/week moderate intensity (when stable)
- •Smoking cessation — reduces CV event risk by 30–50% within 1 year
- •Weight management: target BMI 20–25 kg/m²
- •Alcohol restriction: ≤2 units/day men, ≤1 unit/day women
- •Stress reduction and sleep optimisation
Treatment Goals
🎯Prevention of major adverse cardiovascular events (MACE): MI, stroke, CV death
🎯Symptom control: absence of angina, dyspnoea, oedema
🎯Preservation or improvement of left ventricular function
🎯Quality of life improvement; functional capacity (NYHA class I–II)
🎯Target organ protection: renal function, cognitive function, peripheral vasculature
Monitoring Parameters
- ◆BP and heart rate at every clinical visit
- ◆ECG: at baseline, after medication changes, and when symptomatic
- ◆Echocardiogram: for HF monitoring (EF, wall motion) — annually or after therapy change
- ◆Lipid panel: 4–12 weeks after statin initiation or dose change; then annually
- ◆Renal function and electrolytes (eGFR, K+): within 1–2 weeks of starting ACE inhibitor/ARB/diuretic
- ◆HbA1c if diabetic (target <7%); weight and fluid balance in HF
- ◆INR monitoring for warfarin therapy (target INR 2–3 for most indications)
Escalation Criteria
- →Refractory angina despite maximal medical therapy → invasive assessment (coronary angiography)
- →Worsening HF despite GDMT → device therapy consideration (ICD, CRT) or specialist referral
- →Uncontrolled BP >180/110 on ≥3 agents → secondary hypertension workup
- →New or worsening arrhythmia → cardiology review
- →Acute coronary syndrome: activate emergency pathway immediately
Special Populations
Elderly: start at lower doses; monitor for orthostatic hypotension, renal impairment, and electrolyte disturbances
Diabetes: SGLT2 inhibitors and GLP-1 RAs have established CV benefit in addition to glucose lowering
CKD: ACE inhibitor/ARB renoprotective; avoid NSAIDs; adjust drug doses for eGFR
Pregnancy: many CV drugs contraindicated (ACE inhibitors, statins, warfarin) — specialist review essential
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →